New drug aims to shield patients from Chemo's hidden damage

NCT ID NCT05256745

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing if a drug called azeliragon can protect the heart and brain from damage caused by chemotherapy in women with early-stage breast cancer. Researchers will give azeliragon alongside standard chemotherapy to about 48 participants to see if it's safe and if it reduces heart injury and memory problems. The main goal is to check for serious side effects and see if the drug changes blood markers of heart damage.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Georgetown Lombardi Comprehensive Cancer Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Medstar Washington Hospital Center
RECRUITING

Washington D.C., District of Columbia, 20010, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.